全文获取类型
收费全文 | 2898篇 |
免费 | 164篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 110篇 |
妇产科学 | 57篇 |
基础医学 | 401篇 |
口腔科学 | 72篇 |
临床医学 | 238篇 |
内科学 | 745篇 |
皮肤病学 | 60篇 |
神经病学 | 321篇 |
特种医学 | 93篇 |
外科学 | 300篇 |
综合类 | 4篇 |
一般理论 | 1篇 |
预防医学 | 159篇 |
眼科学 | 25篇 |
药学 | 250篇 |
中国医学 | 5篇 |
肿瘤学 | 244篇 |
出版年
2023年 | 33篇 |
2022年 | 45篇 |
2021年 | 78篇 |
2020年 | 54篇 |
2019年 | 61篇 |
2018年 | 78篇 |
2017年 | 69篇 |
2016年 | 76篇 |
2015年 | 106篇 |
2014年 | 108篇 |
2013年 | 132篇 |
2012年 | 224篇 |
2011年 | 212篇 |
2010年 | 99篇 |
2009年 | 114篇 |
2008年 | 136篇 |
2007年 | 158篇 |
2006年 | 170篇 |
2005年 | 143篇 |
2004年 | 131篇 |
2003年 | 131篇 |
2002年 | 97篇 |
2001年 | 39篇 |
2000年 | 33篇 |
1999年 | 44篇 |
1998年 | 25篇 |
1997年 | 24篇 |
1996年 | 18篇 |
1995年 | 17篇 |
1994年 | 13篇 |
1993年 | 12篇 |
1992年 | 33篇 |
1991年 | 22篇 |
1990年 | 36篇 |
1989年 | 31篇 |
1988年 | 26篇 |
1987年 | 30篇 |
1986年 | 23篇 |
1985年 | 20篇 |
1984年 | 15篇 |
1983年 | 18篇 |
1982年 | 10篇 |
1981年 | 10篇 |
1979年 | 10篇 |
1977年 | 14篇 |
1975年 | 13篇 |
1974年 | 9篇 |
1973年 | 16篇 |
1969年 | 8篇 |
1967年 | 10篇 |
排序方式: 共有3090条查询结果,搜索用时 15 毫秒
21.
Chlorhexidine susceptibility and Eagle effect in planktonic cells and biofilm of nosocomial isolates
Marchi Ana Paula Farrel Côrtes Marina Vásconez Noguera Saidy Rossi Flavia Levin Anna Sara Figueiredo Costa Silvia Perdigão Neto Lauro Vieira 《European journal of clinical microbiology & infectious diseases》2023,42(6):787-792
European Journal of Clinical Microbiology & Infectious Diseases - The aim of this study is to evaluate the chlorhexidine gluconate (CHG) susceptibility in both planktonic cells and biofilm of... 相似文献
22.
Ermanno Bonucci Paola Ballanti Antonietta Martelli Eugenio Mereto Giovanni Brambilla Paolo Bianco Lidia Bufalino 《Calcified tissue international》1992,50(4):314-319
Summary Ipriflavone, a synthetic isoflavone-derived flavonoid, was shown to have inhibitory effect on bone resorption. In order to study its mechanism of action directly on bone, 46 female Wistar rats were divided into six groups and medicated orally for 25 days as follows: groups 1 and 2 were given 1% carboxymethylcellulose solution (vehicle), groups 3, 4, 5, and 6 were administered ipriflavone at doses of 0.178, 0.356, 0.712, and 1.424 mmol/kg/day (suspended in vehicle), respectively. On the 22nd day, parathyroid glands, taken from donor rats, were transplanted in contact with the outer surface of the periosteum of both the right and the left parietal bones of rats from groups 2, 3, 4, 5, and 6. The group 1 rats underwent sham operation. Bone histomorphometry, performed on the ectocranial periosteum of parietal bones, showed that absolute erosion boundary, absolute eroded area, absolute erosion depth, number of tartrate-resistant acid phosphatase (TRAP)-positive polinucleated osteoclasts, and number of TRAP-positive mononucleated cells decreased in ipriflavone-treated rats compared with group 2 rats. The reduction was roughly proportional to the increase of drug dosage and reached statistical significance in rats of groups 5 and 6. The same parameters were extremely low in group 1 rats. Mineral apposition rate did not differ in any of the groups. Significant increase of serum calcium and significant decrease of serum phosphate were found in group 2 rats compared with group 1 rats, whereas no differences from controls were detected in ipriflavone-treated animals.The results demonstrate that ipriflavone has a direct inhibitory effect upon bone resorption, probably by reducing recruitment or differentiation of osteoclasts, rather than by inhibiting the resorption activity of differentiated osteoclasts. Ipriflavone also seems to exert a protective action against parathyroid hormone (PTH) diffusion from the site of parathyroid gland transplantation. 相似文献
23.
Maria Antonietta Sabatino Tina Colombo Cristina Geroni Sergio Marchini Massimo Broggini 《Clinical cancer research》2003,9(14):5402-5408
PURPOSE: Brostallicin (PNU-166196) is a alpha-bromoacrylic DNA minor groove binder, currently in clinical evaluation. This drug has the peculiarity of showing enhanced antitumor activity in cells with high glutathione S-transferase (GST)/glutathione content. The purpose of the study was to study multiple combinations of brostallicin with classical anticancer agents. EXPERIMENTAL DESIGN: The cis-dichloro-diammine-platinum (cDDP)/brostallicin combination was tested in the human colon carcinoma (HCT-116) model transplanted in nude mice. Two treatment schedules were tested: cDDP followed by brostallicin 48 h after or brostallicin followed by cDDP. These two schemes were selected from the observation that tumor cells in vitro show an increased activity of GST 48 h after cDDP treatment. The HCT-116 model was used also to test the irinotecan (cPT-11)/brostallicin combination. The effect of brostallicin in combination with doxorubicin (DX) was studied in the i.v. injected murine L1210 leukemia. Three administration schedules were tested. The antitumor activity of brostallicin and Taxotere was tested on the A549 lung cancer xenografts. RESULTS: In line with the increased GST activity observed after treatment with cDDP, the cDDP/brostallicin interaction was sequence-dependent, leading to a more than additive antitumor effect, without additional toxicity, only when cDDP was given before brostallicin. The antitumor effect of CPT-11 was enhanced significantly by brostallicin cotreatment. A more than additive antitumor effect, without additional toxicity, was observed when DX/brostallicin were sequentially administered in L1210-bearing mice. Finally, additivity was observed when brostallicin/Taxotere simultaneous combination was tested. CONCLUSIONS: Although the precise molecular mechanism of interaction between brostallicin and the other tested cytotoxics has not yet been identified, a clear therapeutic gain is observed in preclinical models when brostallicin is combined with anticancer agents such as cDDP, DX, CPT-11, and Taxotere. These results indicate the potential therapeutic value of brostallicin in cancer combination treatment therapy. 相似文献
24.
25.
Teresa Perillo Alessio Vitiello Marianna Perrotta Antonietta Serino Andrea Manto 《Radiology Case Reports》2022,17(10):3678
We report a case of a 54-year-old man suffering from sciatalgia unresponsive to medical treatment. Imaging revealed a discal cyst the level L3-L4, a rare cause of low back pain, which has characteristic imaging features. In particular, on Magnetic Resonance Imaging it appears as a cystic formation with fluid content, which usually arises from the posterior contour of the intervertebral disc and it frequently has air bubbles within it. The patient underwent surgical treatment with resolution of symptoms. 相似文献
26.
27.
28.
29.
Emmanuel de Billy Marsha Pellegrino Domenico Orlando Giulia Pericoli Roberta Ferretti Pietro Businaro Maria Antonietta Ajmone-Cat Sabrina Rossi Lucia Lisa Petrilli Nicola Maestro Francesca Diomedi-Camassei Marco Pezzullo Cristiano De Stefanis Paola Bencivenga Alessia Palma Rossella Rota Francesca Del Bufalo Luca Massimi Gerrit Weber Chris Jones Andrea Carai Simona Caruso Biagio De Angelis Ignazio Caruana Concetta Quintarelli Angela Mastronuzzi Franco Locatelli Maria Vinci 《Neuro-oncology》2022,24(7):1150
BackgroundDiffuse midline gliomas (DMG) H3K27M-mutant, including diffuse intrinsic pontine glioma (DIPG), are pediatric brain tumors associated with grim prognosis. Although GD2-CAR T-cells demonstrated significant anti-tumor activity against DMG H3K27M-mutant in vivo, a multimodal approach may be needed to more effectively treat patients. We investigated GD2 expression in DMG/DIPG and other pediatric high-grade gliomas (pHGG) and sought to identify chemical compounds that would enhance GD2-CAR T-cell anti-tumor efficacy.MethodsImmunohistochemistry in tumor tissue samples and immunofluorescence in primary patient-derived cell lines were performed to study GD2 expression. We developed a high-throughput cell-based assay to screen 42 kinase inhibitors in combination with GD2-CAR T-cells. Cell viability, western blots, flow-cytometry, real time PCR experiments, DIPG 3D culture models, and orthotopic xenograft model were applied to investigate the effect of selected compounds on DIPG cell death and CAR T-cell function.ResultsGD2 was heterogeneously, but widely, expressed in the tissue tested, while its expression was homogeneous and restricted to DMG/DIPG H3K27M-mutant cell lines. We identified dual IGF1R/IR antagonists, BMS-754807 and linsitinib, able to inhibit tumor cell viability at concentrations that do not affect CAR T-cells. Linsitinib, but not BMS-754807, decreases activation/exhaustion of GD2-CAR T-cells and increases their central memory profile. The enhanced anti-tumor activity of linsitinib/GD2-CAR T-cell combination was confirmed in DIPG models in vitro, ex vivo, and in vivo.ConclusionOur study supports the development of IGF1R/IR inhibitors to be used in combination with GD2-CAR T-cells for treating patients affected by DMG/DIPG and, potentially, by pHGG. 相似文献
30.